Ge Long Hui·2026-03-30 15:29Core Insights - Fosun International (00656.HK) reported a total revenue of RMB 173.4 billion for the fiscal year 2025, a decrease of RMB 18.72 billion or approximately 9.7% year-on-year, primarily due to the cyclical downturn affecting Yuyuan Industrial Co., which saw a revenue decline of about 22.5% [1] - The group's asset base remained robust, with the top four subsidiaries (by revenue) contributing a total revenue of RMB 128.2 billion, accounting for 73.9% of the group's total revenue, an increase of 3.1 percentage points year-on-year [1] - The group's overseas revenue reached RMB 94.86 billion, increasing its share of total revenue from 49.3% to 54.7%, reflecting the success of its globalization strategy [1] Financial Performance - Yuyuan Industrial Co. reported a loss attributable to shareholders of RMB 4.9 billion, compared to a net profit of RMB 130 million in the same period of 2024, due to asset impairment tests on commercial real estate projects and goodwill [2] - Other core businesses showed stable performance, with Fosun Pharma's profit attributable to shareholders reaching RMB 3.37 billion, a year-on-year increase of 21.7%, driven by growth in innovative drug revenues and increased overseas commercialization transactions [2] - Fosun Portugal Insurance also demonstrated solid growth, with profits attributable to shareholders rising to EUR 200 million, up 15.8% year-on-year [2] Strategic Adjustments - The company adhered to financial prudence by recognizing non-cash impairment provisions for goodwill and intangible assets in real estate and some non-core businesses, resulting in a loss attributable to shareholders of RMB 23.4 billion for 2025 [3] - This impairment is part of a strategic asset value optimization process and does not affect the operational stability or cash flow of core businesses, aiming to strengthen the financial foundation for high-quality development [3]